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Abstract
Background and Aims Our goal was to compare the diagnostic accuracy of FISH in the detection of malignancy compared 
with other standard diagnostic modalities, including brush cytology and biopsy specimens over a 10-year period of prospec-
tive data collection.
Methods We conducted a review of all consecutive biliary strictures evaluated between 2006 and 2016. Patients with a final 
pathologic diagnosis or conclusive follow-up were included. We evaluated the performance of FISH polysomy (CEP 3, 7, 
and 17) and 9p21 deletion as well as cholangioscopic biopsy (CBx) and EUS-FNA. Statistical analysis was performed with 
the Mann–Whitney U and Fisher’s exact tests.
Results Of 382 patients with indeterminate strictures, 281 met inclusion criteria. Forty-nine percent were malignant. Cytol-
ogy, FISH polysomy, and FISH polysomy/9p21 showed a specificity of 99.3%. FISH polysomy/9p21 as a single modality 
was the most sensitive at 56% (p < 0.001). The sensitivity of FISH polysomy/9p21 and cytology was significantly higher 
than cytology alone at 63 versus 35% (p < 0.05). EUS-FNA for distal strictures and CBx for proximal strictures increased 
sensitivity from 33 to 93% (p < 0.001) and 48–76% (p = 0.05) in cytology-negative strictures.
Conclusions The high specificity of FISH polysomy/9p21 suggests that a positive result is sufficient for diagnosing malig-
nancy in indeterminate strictures. The significantly higher sensitivity of FISH polysomy/9p21 compared to cytology supports 
the use of FISH in all non-diagnostic cases. Although both EUS-FNA and CBx were complimentary, our results suggest 
that distal strictures should be evaluated by EUS initially. Proximal strictures may be evaluated by FISH first and then by 
CBx if inconclusive.
Keywords Fluorescence in situ hybridization · Biliary strictures · Pancreatic cancer · Cholangiocarcinoma · ERCP · EUS-
FNA
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Introduction
Although several recent therapeutic advances have been 
made with regard to biliary malignancies, the accurate 
diagnosis of malignancy in a biliary stricture remains a 
challenge [1, 2]. At present, biliary brushings obtained for 
cytology during endoscopic retrograde cholangiopancrea-
tography (ERCP) remain the most common first-line diag-
nostic approach [3]. Despite a specificity of 100%, cytol-
ogy has a sensitivity as low as 5–40% for the diagnosis of 
malignancy in biliary strictures [4]. As such, cytology is 
inadequate alone to rule out the presence of malignancy 
without follow-up diagnostic testing.
Fluorescence in situ hybridization (FISH) uses fluores-
cence-labeled probes to evaluate the presence of chromo-
somal abnormalities in cells obtained via routine biliary 
brushings. When FISH is added to routine cytology, sev-
eral groups have demonstrated increased yield in diagnos-
ing biliary malignancy [3, 5–8]. The best characterized 
aneuploid chromosomal regions are on chromosomes 3, 7 
and 17 (CEP 3, 7, 17) [5, 7]. We have previously demon-
strated that the detection of homozygous or heterozygous 
deletion of the 9p21 locus (p16) in addition to polysomy 
increases the diagnostic yield of biliary malignancy [7]. 
Recently, additional loci have been evaluated and shown 
slightly higher sensitivity for the detection of malignancy 
[5].
Although there are multiple reports on different size 
cohorts regarding the utility of FISH in the diagnosis of 
biliary strictures, we report here on the use of this modal-
ity over a 10-year period. Our primary goal was to evaluate 
the accuracy of FISH in this large cohort of prospectively 
followed patients and compare the accuracy to cytology 
and additional diagnostic modalities (such as endoscopic 
ultrasound-fine needle aspiration (EUS-FNA) and chol-




This study was approved by the Institutional Review Board 
of Columbia University and New York Presbyterian Hos-
pital. All consecutive patients who underwent diagnostic 
evaluation for biliary strictures between 2006 and 2016 
were included provided that they had ≥ 12-month follow-
up or a final pathological diagnosis. Among patients with 
concurrent stone disease, only those in whom a significant 
stricture (deemed necessary to both evaluate and treat by 
the performing endoscopist) were included. Patients were 
excluded if sampling was done for abnormalities other 
than a stricture on the cholangiogram or lacked FISH test 
results in their medical record. A stricture was designated 
as benign if at ≥ 12-month follow-up repeat imaging or 
ERCP documented the resolution or stability of prior 
ductal abnormalities. A diagnosis of malignancy was made 
when either biopsy or cytology specimens demonstrated 
malignancy, final pathology was obtained by surgery, or 
if the cause of death was secondary to pancreatobiliary 
malignancy. The diagnosis of PSC was made based on 
cholangiographic findings associated with laboratory 
abnormalities or liver biopsy combined with a lack of 
other etiology of the stricture.
Specimen Collection
Samples were obtained for both cytology and FISH using 
two standard cytology brushes during ERCP (RX cytol-
ogy brush, Boston Scientific, Cambridge, MA or Infinity 
sampling device, US endoscopy, Mentor, OH). Specimens 
were obtained with at least 10 to-and-fro motions at the 
site of the dominant stricture for both cytology and FISH 
specimens. The brush was cut and placed into 15 mL of 
ThinPrep CytoLyt solution (Marlborough, Mass) and was 
transferred to the cytogenetics laboratory within 24 h. For 
the FISH analysis, a separate brush was used (always fol-
lowing the taking of the cytology specimen). The cytology 
from the biliary brushings was then analyzed by a cyto-
pathologist. Samples were classified using the Bethesda 
Category scoring system for cytology, scaled from I to VI: 
“I—non-diagnostic,” “II—negative for malignancy,” “III—
atypical,” “IV—neoplastic: benign or other,” “V—suspi-
cious,” and “VI—positive or malignant.” For this study, 
all non-Bethesda scored cytology results were converted to 
the Bethesda Category scoring system from the pathology 
report. For the purposes of this study, we defined a positive 
cytology result as either Bethesda Categories V or VI (suspi-
cious or malignant cells, positive cytology I) or positive only 
with Bethesda VI (malignant cells, positive cytology II).
Fluorescence In Situ Hybridization (FISH)
Cytology brushes were processed for FISH analysis as 
previously published and hybridized using the Urovysion 
(Abbott Molecular, Des Plaines, Ill) consisting of CEP 3 
(orange), CEP 7 (green), CEP 17 (aqua), and 9p21 (p16, 
gold) [7]. Fluorescent signals were scored on 25–100 cells 
on 4′,6-diamidino-2-phenylindole (DAPI)-stained slides by 
using the Cytovision Imaging system attached to a Nikon 
Eclipse 600 microscope (Applied Imaging, Santa Clara, 
Calif). All FISH samples were analyzed at the Cytopathol-
ogy Laboratory of Columbia University Medical Center. The 
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following criteria were applied to select the cells to score: 
large nuclear size, irregular nuclear shape, patchy DAPI 
stain, and clustered but not overlapped cells. Signals were 
recorded as polysomy when there was a gain of two or more 
chromosomes in at least 5 cells. Homozygous deletion of 
9p21 (p16) was considered when both copies were absent 
in at least 10 cells as per scoring criteria suggested by the 
manufacturer (Abott Molecular, Des Plaines, Ill), or if there 
was a heterozygous deletion in at least 6% of the total cells 
analyzed, the variation that was established by using normal 
specimens in the laboratory. The FISH abnormalities are 
reported in order of severity, i.e., if a patient had polysomy, 
9p21 deletion, and trisomy 7, they were counted as having 
a polysomy.
Statistical Analysis
Demographic characteristics between patients with benign 
and malignant strictures were compared with Fisher’s 
exact test for categorical variables, and the nonparametric 
Mann–Whitney U test for continuous variables. Receiver 
operating characteristic (ROC) curves were then con-
structed. All statistical analyses were performed with SPSS 




In total, 392 consecutive patients underwent 401 ERCP pro-
cedures with tissue obtained for cytology and FISH during 
the study period (Fig. 1). A total of 120 procedures were 
ultimately excluded from our analysis. 99 procedures were 
excluded for lack of adequate follow-up. 19 duplicate proce-
dures were excluded. 2 of the 19 patients had negative FISH 
results on their first procedure, but had positive FISH results 
on the subsequent procedure. Because both procedures in 
these cases occurred within 6 weeks of each other, only the 
most significant FISH abnormality was included. 2 patients 
died without a definitive cause before a definitive diagno-
sis could be made and were excluded. After exclusion of 
patients with inadequate follow-up and duplicate procedures, 
281 patients and procedures were included.
Procedures of paents 
with biliary strictures 
evaluated by FISH n=401
Included  
Final pathology or ≥12 
months follow-up      
n=281 
Non-PSC                             
n=239 
Benign                           
n=104
Malignant                    
n=135
PSC                                   
n=42
Benign                              
n=39  
Malignant                        
n=3          
Excluded
Follow-up pending, lost to 
follow-up, or duplicate 
procedures                      
n=120
<12 months follow up 
n=99
Died before conclusive 
diagnosis made                        
n=2
Excluded duplicate 
procedures                     
n=19
Fig. 1  Study subject selection
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Of the 281 patients that met inclusion criteria, 143 
(50.9%) patients were male with a median age of 65 at 
ERCP (Table 1). 42 patients had a history of PSC, of which 
3 were found to have malignancy. 91 patients had an ERCP 
with stent placement prior to their index procedure. None 
of these patients had a diagnosis of malignancy when bil-
iary sampling was performed. On average, patients diag-
nosed with biliary malignancy were significantly older than 
patients with benign strictures (p = 0.001). Patients with a 
history of stone disease were significantly more likely to 
have a benign stricture (p = 0.001). A total of 169 patients 
had proximal CBD strictures, and 105 patients had distal 
CBD strictures. Distal CBD strictures were significantly 
more likely to be malignant than proximal CBD strictures 
(p = 0.001). Patients with malignant strictures had signifi-
cantly higher median serum CA 19-9 levels (125.5 U/mL vs. 
17.0 U/mL, p = 0.001).
Diagnostic Accuracy
Cytology, when the presence of both suspicious and malig-
nant cells (positive cytology I) was considered positive, had 
a sensitivity and specificity of 35 and 99%, respectively, for 
diagnosing malignancy. However, when only the presence of 
malignant cells was considered a positive (positive cytology 
II), sensitivity fell to 26% though the specificity increased 
to 100%. This change in the sensitivity was not statisti-
cally significant (35 vs. 26%, p = 0.149). The sensitivities 
of cytology I in patients with a previous stent placed and 
those without a previous stent were 25 and 40%, respectively 
(p = 0.088).
FISH, when considering only polysomy of chromosome 
3, 7, and/or 17 as a marker of malignancy, had a sensitiv-
ity and specificity of 45 and 99%, respectively. When we 
included 9p21 heterozygous or homozygous deletions as 
a positive result, FISH sensitivity increased significantly 
to 55% while maintaining a specificity of 99% (p = .001). 
When trisomy 7 or 17 alone was also considered a positive 
FISH result, the sensitivity increased to 59%, though the 
specificity decreased to 91%. The combination of cytology 
I and FISH polysomy or 9p21 deletion (considered positive 
if either was positive) had the highest sensitivity of 63% 
with a preserved specificity of 98% (p < 0.001). The PPV 
and NPV of this strategy were 98 and 73%, respectively 
Table 1  Demographics and baseline data
PSC primary schlerosing cholangitis, CCA cholangiocarcinoma, PAC pancreatic adenocarcinoma, CBD common bile duct
* p values less than 0.001 were reported as 0.001
Entire cohort (n = 281) Malignant (n = 138) Benign (n = 143) p*
Patient baseline characteristics and etiology
Age at ERCP, years, median (IQR) 65 (19.3) 68 (16.0) 61 (19.5) 0.001
Male gender, n (%) 143 (50.9%) 73 (52.9%) 70 (49.0%) 0.551
PSC, n (%) 42 (14.9%) 3 (2.2%) 39 (27.3%) 0.001
Chronic pancreatitis, n (%) 17 (6.0%) 6 (4.3%) 11 (7.7%) 0.318
Autoimmune pancreatitis, n (%) 3 (1.1%) 0 3 (2.1%) 0.248
History of cancer, n (%) 7 (2.5%) 5 (3.6%) 2 (1.4%) 0.275
History of choledocholithiasis, n (%) 22 (7.8%) 1 (0.7%) 21 (14.7%) 0.001
Previous stent placed, n (%) 91 (32.4%) 44 (31.9%) 47 (32.9%) 0.899
Serum CA 19-9, median (IQR) 61.5 (246.8) 125.5 (522.3) 17 (55.5) 0.001
CCA, n (%) – 55 (39.9%) – –
PAC, n (%) – 77 (55.8%) – –
Other, n (%) – 6 (4.3%) – –
Stricture location
Proximal CBD 169 (60.1%) 54 (39.1%) 115 (80.4%) 0.001
Distal CBD 105 (37.4%) 81 (58.7%) 24 (16.8%) 0.001
Pancreatic duct 7 (2.5%) 3 (2.2%) 4 (2.8%) > .99
Cytology result
Bethesda category I—non-diagnostic, n (%) 13 (4.6%) 3 (2.2%) 10 (7.0%) 0.085
Bethesda category II—benign, n (%) 100 (35.6%) 25 (18.1%) 75 (52.4%) 0.001
Bethesda category III—atypical, n (%) 118 (42.0%) 61 (44.2%) 57 (39.9%) 0.471
Bethesda category IV—neoplastic, n (%) 1 (0.4%) 1 (0.7%) 0 0.491
Bethesda category V—suspicious, n (%) 13 (4.6%) 12 (8.7%) 1 (0.7%) 0.001
Bethesda category VI—malignant, n (%) 36 (12.8%) 36 (26.1%) 0 0.001
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(Table 2). The sensitivities of cytology I and FISH polysomy 
or 9p21 deletion in patients with a previous stent placed and 
those without a previous stent were 66 and 62%, respectively 
(p = 0.707).
It is notable that only two false-positive results were 
included in our study. One patient had a false-positive 
result using FISH, showing polysomies of chromosomes 7 
and 17 in 6.3% of cells analyzed. This patient had adequate 
follow-up and subsequently underwent a cholecystectomy 
for chronic cholecystitis. The gallbladder was noted to be 
perforated and necrotic; however, no dysplasia was noted 
upon pathological analysis. Although we considered this 
a false-positive result as the patient had adequate follow-
up of > 12 months with resolution of a biliary stricture, 
detailed evaluation (i.e., ERCP) of the biliary tree has not 
been performed since the initial sample was obtained. A 
second patient had a false-positive cytology result, Bethesda 
Category V—suspicious. FISH testing was negative for pol-
ysomy and 9p21 (p16) deletion. This patient had a history of 
PSC. The initial brushing contained atypical epithelial cells 
with at least severe dysplasia suspicious for malignancy, 
but results of subsequent examinations up to two years of 
follow-up were negative for malignancy or cytologic atypia.
Our cohort included a small number of PSC patients 
and 3 PSC-associated malignancies. In patients with PSC, 
a sensitivity for cytology could not be calculated as there 
were true positive cytology results in PSC patients. FISH 
polysomy and 9p21 deletion had a sensitivity and specific-
ity of 33.3 and 97.4%, respectively. Of the 6 patients with a 
CA 19-9 > 129 U/mL, 1 developed CCA in our cohort. In 
addition, none of the patients classified as benign PSC with 
an elevated CA 19-9 had aneuploidy.
Abnormalities Identified by FISH
A total of 102 (36%) patients in the study had at least one 
abnormal FISH result (Table 3). Of these patients with 
abnormal FISH results, 83 (81%) of these patients had 
malignancies. Sixty-two (22%) patients had FISH results 
showing polysomy of chromosome 3, 7, and/or 17, of which 
61 (98%) had malignancy. The most common abnormal-
ity observed was polysomy, but 9p21 (p16) deletion alone 
was observed in 19.3% of all malignant cases (50.0% were 
homozygous, and 50.0% were heterozygous deletions). 
Though trisomy 7 was observed in 24 of 102 (23.5%) of 
cases with FISH abnormalities, only 6 of 24 (25%) of these 
cases were malignant.
Yield of Additional Diagnostic Modalities 
in Cytology‑Negative Cases of Malignancy
We also evaluated the added value of additional sampling 
methods, such as EUS-FNA, or cholangioscopic biopsies 
in patients with cytology-negative strictures. 88 patients 
had cytology-negative malignant biliary strictures. 60 of 88 
(68%) had a Bethesda Category III (atypical) result, 24 of 
88 (27%) had a Bethesda Category II (benign) result, 3 of 88 
(3%) had a Bethesda Category I (non-diagnostic) result, and 
only 1 of 88 (1%) had a Bethesda Category IV (neoplastic) 
result.
Table 2  Performance characteristics of the studied diagnostic modalities
FISH fluorescence in situ hybridization, PPV positive predictive value, NPV negative predictive value, AUC area under the curve
Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%) AUC p value
Cytology I 35.29 99.30 97.96 61.21 67.62 0.670 –
Cytology II 25.90 100 100 57.96 63.35 0.630 0.118
FISH polysomy 44.20 99.30 98.39 64.84 72.24 0.718 0.139
FISH polysomy + 9p21 55.80 99.30 98.72 69.95 77.94 0.775 < 0.001
FISH polysomy + 9p21 + trisomy 7 59.56 90.91 86.17 70.27 75.09 0.738 < 0.001
Cytology I/FISH polysomy 54.35 98.60 97.40 69.12 76.87 0.765 0.001
Cytology I/FISH polysomy + 9p21 63.04 98.60 97.75 73.44 81.14 0.805 < 0.001
Table 3  Summary of abnormal 
FISH results
A total of 102 patients in the study had abnormal FISH results, and 83 patients had confirmed malignancy. 
The false-positive polysomy is the only false-positive FISH test observed
Abnormality observed Abnormal FISH 
cohort n = 102 
(%)
Malignant n = 83 (%) Benign n = 19 (%)
Polysomy (± 9p21 deletion or trisomy 7) 62 (60.9%) 61 (73.5%) 1 (5.3%)
9p21 deletion (± trisomy 7) alone 16 (15.7%) 16 (19.3%) 0
Trisomy 7 alone 24 (23.5%) 6 (7.2%) 18 (94.7%)
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There were 69 patients with distal strictures and negative 
cytology. In this cohort, 35 patients underwent EUS and 28 
were found to have malignancy. In this population of patients 
who underwent testing by FISH and EUS-FNA, FISH alone 
was diagnostic in 3 (10.0%), EUS-FNA alone in 18 (60.0%), 
and both were positive in 7 (23.3%) cases. The sensitivity 
and NPV of FISH and EUS-FNA in the entire cohort (in an 
intention to diagnose analysis including patients who had 
only one diagnostic study) were 77.8 and 70.6% compared to 
37.8 and 46.2% for FISH alone (p = 0.001) (Table 4). When 
only considering patients who had additional sampling done 
in addition to FISH and cytology, the sensitivity and NPV 
of FISH and EUS-FNA were 93.3 and 71.4% compared to 
33.3 and 20.0% for FISH alone (p = 0.001).
There were 157 patients with proximal strictures with 
negative cytology. Among patients with proximal biliary 
strictures and a negative cytology result who were found to 
have malignancy (n = 43), 25 (58.1%) underwent both FISH 
and cholangioscopic biopsies (CBx). In this population of 
indeterminate proximal strictures, FISH alone was diagnos-
tic in 7 (28.0%), CBx alone in 7 (28.0%), and both were 
positive in 5 (20.0%) cases. In the entire cohort of patients 
with cytology-negative proximal strictures, the sensitivity 
and NPV of FISH and CBx were 67.4 and 89.0% compared 
to 51.2 and 84.3% for FISH alone (p = 0.133). When only 
considering patients who had additional sampling done in 
addition to FISH and cytology, the sensitivity and NPV of 
FISH and CBx were 76.0 and 89.3% compared to 48.0 and 
79.4% for FISH alone (p = 0.05).
Discussion
For both technical and biological reasons, the diagnosis of 
malignancy in bile duct strictures remains difficult. Although 
cytological brushings are widely available and have a spec-
ificity ranging from 87 to 100%, one cannot rely on this 
modality alone due to low sensitivities of 4–60% [3, 8]. 
FISH has been shown to add considerable value to cytology, 
increasing the sensitivity while maintaining a comparable 
specificity to cytology alone when these two modalities are 
used together [3, 5, 7 –15].
This study presents one of the largest cohorts using FISH 
for the diagnosis of malignancy in biliary strictures. Per-
haps the clinically most important finding was the confir-
mation that both FISH polysomy and the addition of 9p21 
heterozygous or homozygous deletion detected in biliary 
brush specimens have a specificity of 98–100%. Overall, 
this high specificity provides strong evidence for considering 
a positive FISH result sufficient for the diagnosis of biliary 
malignancy. However, an important caveat has to be made 
for PSC. Our cohort contained relatively few PSC patients, 
making significant analysis difficult. Prior studies focused 
on this population have shown FISH abnormalities detected 
in patients with pre-malignancy or inflammation harboring 
these aneuploidies [16, 17].
Our study also shows that FISH has a significantly higher 
diagnostic yield than cytology alone. While the sensitivi-
ties of FISH (polysomy) and cytology were not significantly 
different, the inclusion of 9p21 deletion as a positive FISH 
result resulted in a significantly higher sensitivity. The sen-
sitivity of the combination of cytology and FISH polysomy 
or polysomy and 9p21 deletion was significantly higher than 
sensitivity of cytology alone. Our results are comparable 
to sensitivities and specificities observed in prior studies at 
other institutions, and we summarized the characteristics of 
these studies in Table 5 for comparison [3, 5, 7, 8, 11–15]. 
We also compared the sensitivity of cytology in patients 
with a previous biliary stent placement and without, but 
found no significant difference. The presence of a stent can 
increase the likelihood of observing reactive atypia and has 
been previously studied as a cause of false-negative results 
in endoscopic brush cytology [18].
Although many other studies included trisomy 7 in their 
definitions of positive FISH results, our data (like others) 
showed a decrease in specificity by 10% when we included 
Table 4  FISH and EUS-FNA/CBx in cytology-negative cohort
Diagnostic modality Proximal Distal
SN NPV SN NPV
n = 157 n = 69
All cytology-negative cases
FISH polysomy/9p21 deletion 51.2% 84.3% 37.8% 46.2%
FISH poly/9p21 ± EUS-FNA or CBx 67.4% 89.0% 77.8% 70.6%
n = 75 n = 35
Cytology-negative cases with EUS-FNA or CBx
FISH polysomy/9p21 deletion 48.0% 79.4% 33.3% 20.0%
FISH poly/9p21 ± EUS-FNA or CBx 76.0% 89.3% 93.3% 71.4%
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this as an indication of malignancy [3, 11–13]. In our prac-
tice, trisomy 7 is considered an equivocal result and is not 
sufficient on its own for diagnosis. Trisomy 7 has been 
previously shown to be prevalent in PSC-associated non-
malignant strictures and due to the low overall specificity, 
and the possibility of this aneuploidy occurring in benign 
disease, was not considered a positive result for our pur-
poses [3, 19].
For those patients with cytology-negative malignan-
cies, the added benefit of FISH and complimentary CBx or 
EUS-FNA was examined. CBx showed a borderline signif-
icant benefit when compared to FISH in the entire cohort 
of cytology-negative proximal biliary strictures. EUS-
FNA was found to have significant added benefit in the 
diagnosis of distal biliary strictures. Although only 61% 
of all patients had either EUS-FNA or CBx, these data 
would suggest that the evaluation of distal biliary stric-
tures should start with brush cytology and EUS-FNA and 
specimens should be retained for FISH analysis in negative 
cases. On the other hand, for proximal strictures we would 
recommend cytology and FISH upfront and reserve CBx 
for those cases where a diagnosis is not established.
There are several limitations to this study, which may 
impact the generalized conclusions from the results. 
First, 25% of all procedures screened for inclusion were 
excluded from the subject population because they lacked 
adequate follow-up. Also, recent works have suggested 
somewhat higher sensitivity with the use of an alterna-
tive set of FISH probes and it is conceivable that a few 
FISH-negative cases could be identified by the use of these 
additional loci [5]. There were also a relatively small num-
ber of PSC patients (42 of 279; 15%) albeit the rate of 
cholangiocarcinoma in this population is consistent with 
the previously reported rate (5–36%) [20].
In summary, our results support the use of FISH 
(defined as positive by either CEP 3,7,17 polysomy and/or 
heterozygous or homozygous p16 deletion)) as sufficient 
for the diagnosis of cancer in non-PSC patients. FISH 
clearly increases the diagnostic yield of routine cytol-
ogy without compromising the specificity in a primarily 
non-PSC-enriched population and does not require any 
additional procedures. We would advocate for a sequential 
analysis of specimens, with retention of brush specimens 
at all sampling procedures for FISH. Importantly, FISH 
specimens can be stored for several days. Therefore, our 
algorithm for distal strictures would be cytology/EUS-
FNA first followed by FISH in negative cases and cytol-
ogy/FISH first in proximal strictures followed by cholan-
gioscopy in negative cases. However, prospective studies, 
incorporating cost analyses, will be needed to validate this 
approach.
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